Skip to contentLAMPERT MARK N — CELL THERAPEUTICS INC insider: 224 transactions · InsiderLensLAMPERT MARK N
- See Explanation of Responses at CELL THERAPEUTICS INC · on record since Jun 28, 2023
- Former 10% Owner at Therapeutics Acquisition Corp. · on record since Dec 20, 2023
- 10% owner at enGene Holdings Inc. · on record since Nov 13, 2023
- 10% owner at Therapeutics Acquisition Corp. · on record since Nov 6, 2023
- See Remarks; Former 10% Owner at Rain Enhancement Technologies Holdco, Inc. · on record since Apr 27, 2021
- 10% owner at Allakos Inc. · on record since Jan 26, 2024
- 10% owner at Xenon Pharmaceuticals Inc. · on record since Sep 12, 2016
- See Explanation of Responses at TF FINANCIAL CORP · on record since Oct 31, 2024
- See Explanation of Responses at PALVELLA THERAPEUTICS, INC. · on record since Dec 17, 2024
- See Explanation of Responses at 4D Molecular Therapeutics, Inc. · on record since Nov 13, 2024
- See Explanation of Responses at Olema Pharmaceuticals, Inc. · on record since Dec 4, 2024
- See Explanation of Responses at KENT FINANCIAL SERVICES INC · on record since Dec 28, 2011
- Director at IMMUNIC, INC. · on record since Feb 27, 2026
- See Explanation of Responses at IMMUNIC, INC. · on record since Feb 27, 2026
- 10% owner at Rain Enhancement Technologies Holdco, Inc. · on record since May 25, 2021
- 10% owner at AVIGEN INC \DE · on record since Jan 21, 2009
- 10% owner at DYNAVAX TECHNOLOGIES CORP · on record since Jul 29, 2009
- 10% owner at ADOLOR CORP · on record since Sep 24, 2009
- 10% owner at ARQULE INC · on record since Sep 21, 2009
- 10% owner at TARGACEPT INC · on record since Jul 16, 2009
- 10% owner at FIRST ALBANY COMPANIES INC · on record since Sep 10, 2009
- 10% owner at MEDICINOVA INC · on record since Dec 24, 2009
- 10% owner at COMBINATORX, INC · on record since Dec 24, 2009
- 10% owner at NEUROBIOLOGICAL TECHNOLOGIES INC /CA/ · on record since Oct 23, 2009
- 10% owner at NEUROCRINE BIOSCIENCES INC · on record since Mar 29, 2010
- 10% owner at SUPERGEN INC · on record since Apr 21, 2010
- 10% owner at Celera CORP · on record since Mar 23, 2011
- Director at MoonLake Immunotherapeutics · on record since Apr 2, 2026
- 10% owner at MoonLake Immunotherapeutics · on record since Apr 2, 2026
- 10% owner at CAPRIUS INC · on record since Jun 29, 2011
- 10% owner at LIGAND PHARMACEUTICALS INC · on record since Aug 22, 2011
- 10% owner at ICAGEN INC · on record since Sep 9, 2011
- 10% owner at PALATIN TECHNOLOGIES INC · on record since Oct 7, 2011
- 10% owner at ARRAY BIOPHARMA INC · on record since Dec 5, 2011
- Director at ARENA PHARMACEUTICALS INC · on record since Oct 21, 2003
- 10% owner at ARENA PHARMACEUTICALS INC · on record since Oct 21, 2003
- See Explanation of Responses at NEUROCRINE BIOSCIENCES INC · on record since Feb 10, 2012
- Director at DISCOVERY PARTNERS INTERNATIONAL INC · on record since Dec 30, 2016
- 10% owner at DISCOVERY PARTNERS INTERNATIONAL INC · on record since Dec 30, 2016
- 10% owner at ChemoCentryx, Inc. · on record since Aug 31, 2012
- 10% owner at RIGEL PHARMACEUTICALS INC · on record since May 15, 2013
- 10% owner at XOMA LTD /DE/ · on record since May 18, 2026
- 10% owner at Oncothyreon Inc. · on record since Jun 7, 2013
- See Explanation of Responses at LIGAND PHARMACEUTICALS INC · on record since Mar 26, 2014
- See Explanation of Responses at Regado Biosciences Inc · on record since Mar 25, 2014
- 10% owner at Regado Biosciences Inc · on record since Feb 10, 2014
- See Explanation of Responses at Oncothyreon Inc. · on record since Jul 16, 2014
- See Explanation of Responses at ARRAY BIOPHARMA INC · on record since Jul 10, 2014
- See Explanation of Responses at TARGACEPT INC · on record since Aug 21, 2015
- 10% owner at CELL THERAPEUTICS INC · on record since Dec 14, 2015
- See Explanation of Responses at ChemoCentryx, Inc. · on record since Nov 5, 2015
- Director at Oncothyreon Inc. · on record since Jun 27, 2016
- 10% owner at NOVELLUS SYSTEMS INC · on record since Jun 22, 2017
- 10% owner at GLYCOMIMETICS INC · on record since May 11, 2017
- 10% owner at CONCERT PHARMACEUTICALS, INC. · on record since Sep 29, 2017
- See Explanation of Responses at CAPRIUS INC · on record since Jul 18, 2017
- 10% owner at Regulus Therapeutics Inc. · on record since Nov 27, 2017
- 10% owner at Syndax Pharmaceuticals Inc · on record since Dec 8, 2017
- 10% owner at PALVELLA THERAPEUTICS, INC. · on record since Nov 26, 2018
- 10% owner at Immune Design Corp. · on record since Nov 9, 2018
- 10% owner at Calithera Biosciences, Inc. · on record since Jul 1, 2019
- 10% owner at FIVE PRIME THERAPEUTICS INC · on record since Oct 31, 2019
- 10% owner at CYTOKINETICS INC · on record since Dec 12, 2019
- 10% owner at Merus N.V. · on record since Jan 21, 2020
- 10% owner at IDEAYA Biosciences, Inc. · on record since Jun 22, 2020
- 10% owner at Principia Biopharma Inc. · on record since Aug 20, 2020
- See Explanation of Responses at Tokai Pharmaceuticals Inc · on record since Dec 28, 2020
- 10% owner at CytomX Therapeutics, Inc. · on record since Dec 28, 2020
- 10% owner at Olema Pharmaceuticals, Inc. · on record since Nov 20, 2020
- See Explanation of Responses at CYTOKINETICS INC · on record since Nov 20, 2020
- See Explanation of Responses at FIVE PRIME THERAPEUTICS INC · on record since Nov 13, 2020
- 10% owner at Tokai Pharmaceuticals Inc · on record since Oct 5, 2020
- See Explanation of Responses at DISCOVERY PARTNERS INTERNATIONAL INC · on record since Feb 19, 2021
- See Explanation of Responses at CytomX Therapeutics, Inc. · on record since Feb 18, 2021
- See Explanation of Responses at IDEAYA Biosciences, Inc. · on record since Feb 4, 2021
- 10% owner at Repare Therapeutics Inc. · on record since Nov 8, 2021
- 10% owner at Cullinan Therapeutics, Inc. · on record since Jan 10, 2022
- 10% owner at Verastem, Inc. · on record since Feb 7, 2022
- 10% owner at 4D Molecular Therapeutics, Inc. · on record since Jun 27, 2022
- Director at XOMA LTD /DE/ · on record since May 20, 2022
- Director at Olema Pharmaceuticals, Inc. · on record since Jun 14, 2022
- 10% owner at EPIX Pharmaceuticals, Inc. · on record since Jul 21, 2022
- Director at CELL THERAPEUTICS INC · on record since Aug 11, 2022
- 10% owner at TF FINANCIAL CORP · on record since Dec 22, 2022
- Director at Rain Enhancement Technologies Holdco, Inc. · on record since Nov 10, 2022
- Director at Kymera Therapeutics, Inc. · on record since Jan 13, 2023
- See Remarks and Footnotes at Kymera Therapeutics, Inc. · on record since Aug 25, 2020
- 10% owner at Structure Therapeutics Inc. · on record since Feb 13, 2023
Insider trading activity of LAMPERT MARK N
- Transactions on record
- 224
- since Oct 21, 2003
- Open-market buys
- 102
- $66.1M
- Open-market sells
- 28
- $80.1M
- Companies traded
- 26
- last filing Jun 20, 2023
Figures computed from official regulatory filings — methodology.
Companies where LAMPERT MARK N has traded
- Kymera Therapeutics, Inc.11 tx · $19.6M · Jun 20, 2023
- CELL THERAPEUTICS INC38 tx · $71M · Aug 11, 2022
- Rain Enhancement Technologies Holdco, Inc.27 tx · $19.1M · Apr 27, 2021
- Merus N.V.6 tx · $11.7M · Apr 1, 2021
- Tokai Pharmaceuticals Inc12 tx · Dec 28, 2020
- XOMA LTD /DE/8 tx · $18.6M · Dec 20, 2019
- Calithera Biosciences, Inc.6 tx · $1.2M · Nov 22, 2019
- FIVE PRIME THERAPEUTICS INC9 tx · $113.8K · Oct 31, 2019
- Xenon Pharmaceuticals Inc.12 tx · $81.6K · Mar 29, 2018
Track record of LAMPERT MARK N
Statistical track record
Free- Open-market buys
- 106
- Last buy
- Mar 30, 2021
Win rates and median returns are available with a free account (5 insiders/month).
Create a free account→Transaction history of LAMPERT MARK N
Co-insiders of LAMPERT MARK N
This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →
6 tx · $106.7K · Jun 1, 2017
| Company | Filed | Type | Qty | Price | Value · USD | Src |
|---|
| Jun 20, 2023 | AwardD | 12,000 | 0.00 USD | $0 | SEC |
| Aug 11, 2022 | OtherD | -2,280 | — | — | SEC |
| Aug 11, 2022 | Other | 3,754,000 | — | — | SEC |
| Aug 11, 2022 | Sell | -1,289,434 | 6.12 USD | $7.9M | SEC |
| Aug 11, 2022 | Sell | -3,850,803 | 6.12 USD | $23.6M | SEC |
| Aug 11, 2022 | Other | 2,426,666 | — | — | SEC |
| Aug 11, 2022 | Sell | -469,040 | 6.12 USD | $2.9M | SEC |
| Aug 11, 2022 | Sell | -2,890,723 | 6.12 USD | $17.7M | SEC |
| Aug 11, 2022 | Other | 1,519,999 | — | — | SEC |
| Aug 11, 2022 | OtherD | -1,024 | — | — | SEC |
| Aug 11, 2022 | Other | 682,666 | — | — | SEC |
| Aug 11, 2022 | OtherD | -3,640 | — | — | SEC |
| Aug 11, 2022 | OtherD | -5,631 | — | — | SEC |
| Apr 27, 2021 | Other | 553,359 | — | — | SEC |
| Apr 27, 2021 | Other | 115,293 | — | — | SEC |
| Apr 27, 2021 | Award | 546,346 | 17.00 USD | $9.3M | SEC |
| Apr 27, 2021 | Other | 134,515 | — | — | SEC |
| Apr 27, 2021 | OtherD | -837,397 | — | — | SEC |
| Apr 27, 2021 | Award | 38,858 | 15.93 USD | $619K | SEC |
| Apr 27, 2021 | OtherD | -134,515 | — | — | SEC |
| Apr 27, 2021 | Award | 10,876 | 14.90 USD | $162.1K | SEC |
| Apr 27, 2021 | Award | 14,790 | 14.90 USD | $220.4K | SEC |
| Apr 27, 2021 | Award | 53,303 | 15.93 USD | $849.1K | SEC |
| Apr 27, 2021 | Other | 1,068,554 | — | — | SEC |
| Apr 27, 2021 | OtherD | -84,350 | — | — | SEC |